News | February 10, 2024
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Ocular hypertension affects over 5% of all adults; the eye does not properly drain fluid, causing eye pressure to build up
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)